Uterine Serous Cancers: Advances and Novel Approaches and James Stuart Ferriss

BMJ talk medicine

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. James Stuart Ferriss to discuss advances and novel approaches in uterine serous cancers. Dr. Ferriss is an assistant professor in the Kelly Gynecologic Oncology division, Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine. He is the program director of the Montz fellowship in gynecologic oncology. Highlights: •Uterine serous carcinomas represent less than 10% of all uterine cancers, but 39% of disease specific deaths. •Surgery remains the cornerstone of treatment. •Our understanding of the molecular drivers of this uncommon cancer supports new, targeted therapies. •Adjuvant treatment of advanced and recurrent uterine serous carcinomas should be based on HER2 expression. • Ongoing clinical trials will further define the role of immunotherapy, WEE1 inhibitors, and PARP inhibitors in uterine serous carcinoma.